According to our new research study on “Oligonucleotide Synthesis MarketForecast to 2027 – Global Analysis – by Product, Application, End User, and Geography,” the global oligonucleotide synthesis market size is estimated to reach US$ 3,971.72 million by 2027 from US$ 1,584.16 million in 2018; it is estimated to grow at a CAGR of 11.1% during 2019–2027.
Download PDF Sample Copy at:
https://www.theinsightpartners.com/sample/TIPBT00002549/
The report highlights trends prevailing in the market and factors driving its growth. The oligonucleotide synthesis market trends are attributed to the rising applications of synthesized oligonucleotides, increasing investments for synthetic biology, and technological advancements in genome editing tools However, the growth of the market is restrained by factors such as renewed regulations for biotechnology.
Thermo Fisher Scientific Inc; GenScript; Synthomics, Inc; Ansa Biotechnologies, Inc; Iridia, Inc; Helixworks; Keasling Lab; Molecular Assemblies; Twist Bioscience; Evonetix; DNA Script; Nuclera Nucleics Ltd; Camena Bio are among the leading companies in the market. The oligonucleotide synthesis market share is anticipated to flourish with the development of new innovative products by market players.
Globally, synthetic biology has set benchmark with its innovations and dynamic results. The industry has attracted various global leaders to invest for synthetic biology. For instance, synthetic DNA manufacturer DNA Script announced a Series A fundraising of 11 million euros ($13 million) led by Illumina Ventures, with additional investment from Merck Ventures BV, the corporate venture arm of Merck KGaA, plus existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners.
Also, in July 2018, Evonetix Awarded Innovate UK Funding for £1.3 million ($1.75M) Gene Synthesis Project. Innovate UK, the UK’s innovation agency, will co-fund the £1.3 million project, which will be undertaken in collaboration with Durham University. Furthermore, synthetic biology company Zymergen has received US$ 44 million funds in 2015 from investors such as Transcript, AME Cloud Ventures, Data Collective, Draper Fisher Jurvetson, HVF, Innovation Endeavors, Obvious ventures, True Ventures, and Two Sigma Ventures. In addition, in 2016, Zymergen raised US$130 million in Series B funding, which was led by SoftBank Group.
Thus, the rising investments for development of synthetic biology techniques is expected to support oligonucleotide synthesis market during the forecast period.
About The Insight Partners:
The Insight Partners is a one top industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Manufacturing and Construction, Technology, Chemicals and Materials.
We offer our clients multiple ways to customize research as per their specific needs and budget.
Contact us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
